Page last updated: 2024-08-24

azelnidipine and 8-hydroxy-2'-deoxyguanosine

azelnidipine has been researched along with 8-hydroxy-2'-deoxyguanosine in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Sugaya, T; Suzuki, T; Ueda, Y	1
Ito, S; Mori, T; Nako, K; Ogawa, S	1
Fujiwara, N; Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Sugaya, T; Ueda, Y	1
Inoue, T; Komoda, H; Node, K	1

Trials

3 trial(s) available for azelnidipine and 8-hydroxy-2'-deoxyguanosine

Article	Year
Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. The American journal of the medical sciences, 2007, Volume: 333, Issue:6 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Amlodipine; Antioxidants; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Deoxyguanosine; Dihydropyridines; Fatty Acid-Binding Proteins; Female; Heart Rate; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Proteinuria	2007
Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertension research : official journal of the Japanese Society of Hypertension, 2008, Volume: 31, Issue:6 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Azetidinecarboxylic Acid; C-Reactive Protein; Calcium Channel Blockers; Creatinine; Deoxyguanosine; Diabetic Nephropathies; Dihydropyridines; Dinoprost; Drug Therapy, Combination; Female; Humans; Interleukin-6; Male; Middle Aged; Oxidative Stress	2008
Additional renoprotective effects of azelnidipine combined with angiotensin receptor blockers in patients with diabetic nephropathy. Clinical nephrology, 2008, Volume: 70, Issue:5 Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Blockers; Creatinine; Deoxyguanosine; Diabetic Nephropathies; Dihydropyridines; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acid-Binding Proteins; Female; Follow-Up Studies; Humans; Kidney; Male; Middle Aged; Treatment Outcome	2008

Other Studies

1 other study(ies) available for azelnidipine and 8-hydroxy-2'-deoxyguanosine

Article	Year
Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker. Clinical and experimental hypertension (New York, N.Y. : 1993), 2010, Volume: 32, Issue:2 Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Azetidinecarboxylic Acid; Biomarkers; C-Reactive Protein; Calcium Channel Blockers; Deoxyguanosine; Dihydropyridines; Female; Humans; Hypertension; In Vitro Techniques; Inflammation Mediators; Interleukin-6; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; Oxidative Stress	2010

Article

Year

Anti-inflammatory properties of azelnidipine, a dihydropyridine-based calcium channel blocker.

Clinical and experimental hypertension (New York, N.Y. : 1993), 2010, Volume: 32, Issue:2

Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Azetidinecarboxylic Acid; Biomarkers; C-Reactive Protein; Calcium Channel Blockers; Deoxyguanosine; Dihydropyridines; Female; Humans; Hypertension; In Vitro Techniques; Inflammation Mediators; Interleukin-6; Interleukin-8; Leukocytes, Mononuclear; Male; Middle Aged; Oxidative Stress

2010